利拉鲁肽延缓2型糖尿病进展的潜在机制:中国学者的研究证据  

Underlying mechanism of Liraglutide in delaying the progression of type 2 diabetes:Evidence from China

作　　者：张晶晶[1] 魏蕊[1] 杨进[1] 洪天配[1] 

机构地区：[1]北京大学第三医院内分泌科,100191

出　　处：《中国糖尿病杂志》2015年第12期1057-1060,共4页Chinese Journal of Diabetes

基　　金：国家自然科学基金(81270858;81400798;81400767;81500626;81570692)

摘　　要：胰岛β细胞功能障碍和IR是T2DM发生发展的重要因素。因此,保护β细胞功能和改善IR将可望延缓T2DM的进展。然而,传统降糖药物单药治疗对于延缓T2DM进展的作用非常有限。最新的研究显示,利拉鲁肽可通过多种机制保护β细胞功能和改善IR,从而延缓T2DM进展。本文将对我国学者在该领域中的相关研究进展进行综述。Islet β-cell dysfunction and insulin resistance are two important factors for the development and progression of type 2 diabetes mellitus（T2DM）.Therefore,protection of isletβ-cell function and improvement of insulin resistance are promising in delaying the progression of T2DM.However,monotherapy using conventional anti-hyperglycemic agent plays a limited role in delaying the progression of T2DM.Recent studies have shown that Liraglutide as a glucagon-like peptide-1 receptor agonist can protect islet β-cell function and incresae insulin sensitivity,thereby delaying the progression of T2DM,through multiple mechanisms.Here we will summarize the research progress in this field in China.

关 键 词：胰升血糖素样肽-1 利拉鲁肽 胰岛Β细胞功能 胰岛素抵抗 

分 类 号：R587.1[医药卫生—内分泌]